CJC-1295: Days of GH Elevation, Zero Efficacy Trials

The short version

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, engineered to last far longer than the natural molecule. In healthy adults, a single subcutaneous dose raised GH two- to ten-fold for at least six days and kept IGF-1 above baseline for nine to eleven days ^[11]. In a second study, basal GH rose approximately 7.5-fold and pulsatile GH secretion was preserved throughout the sustained elevation ^[12]. Those are the published human data: two pharmacology papers involving small numbers of healthy volunteers.

There is no completed controlled trial of CJC-1295 for any clinical outcome in any disease or health condition. The compound is not approved by any regulatory authority, and its original DAC (Drug Affinity Complex) development program was discontinued. Its presence in online protocols for anti-aging, muscle gain, and body recomposition is based entirely on mechanism and animal pharmacology, not human outcome evidence. This page reports what was studied; it gives no human dose and no medical advice.

What it is

CJC-1295 is a synthetic peptide built on the first 29 residues of human growth hormone-releasing factor — hGRF(1-29) — carrying four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) that stabilize the alpha-helix and block the enzymatic cleavage and chemical degradation that limit the native hormone's half-life ^[8].

Two chemically distinct variants circulate under the same name. CJC-1295 DAC ("Drug Affinity Complex") adds a maleimidopropionyl linker at the C-terminus that forms a covalent bond with a cysteine on circulating albumin, extending its plasma half-life to roughly 5.8–8.1 days — approaching albumin's own half-life ^[11]. CJC-1295 no-DAC, also called Modified GRF 1-29, carries the four protective substitutions but lacks the albumin-binding moiety and clears far more quickly. These two are pharmacokinetically very different, a distinction that is routinely collapsed in community discussions and marketing.

How it works

CJC-1295 binds the growth hormone-releasing hormone receptor (GHRHR) on anterior-pituitary somatotrophs, activating the Gs/cAMP/PKA signaling cascade. This stimulates synthesis and pulsatile secretion of growth hormone, which in turn drives hepatic production of insulin-like growth factor 1 (IGF-1) ^[8].

The key point the pharmacology established — and that the 2006 human study confirmed — is that the sustained, days-long presence of CJC-1295 in circulation elevates baseline GH and IGF-1 while preserving pulsatile GH secretion ^[12]. This is noteworthy because continuous GHRH-receptor stimulation might be expected to exhaust the pituitary's GH reserve, but pulsatility persisted. The 2025 Nature Reviews Endocrinology synthesis of GHRH and its analogs situates CJC-1295 within the broader class that includes sermorelin and tesamorelin, describing the receptor-signaling rationale and the design logic for long-acting variants ^[8].

What the research shows

Authoritative class review. A 2025 Nature Reviews Endocrinology article synthesizes the pharmacology of GHRH and its synthetic analogs — the class that includes CJC-1295, sermorelin, and tesamorelin — covering receptor signaling, long-acting design rationale, and the therapeutic landscape ^[8].

Anti-doping identification. In 2010, CJC-1295 was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown pharmaceutical preparation seized in an anti-doping context — confirming its presence in gray-market supply and that analytical detection is established ^[9].

Serum proteomic shifts (n=11 men). In eleven healthy young adult men, a single CJC-1295 dose shifted the serum proteome detectably: apolipoprotein A1 and a transthyretin isoform decreased; immunoglobulin and albumin-fragment species increased. The immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, suggesting candidate biomarkers of GH/IGF-1 axis activation ^[10].

Sustained GH and IGF-1 elevation (n=healthy adults, ages 21–61). In the primary pharmacology study, single subcutaneous doses of 30 or 60 micrograms/kg produced dose-dependent two- to ten-fold increases in mean plasma GH lasting six or more days, and 1.5- to 3-fold increases in IGF-1 for 9–11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated half-life of CJC-1295 in this study was 5.8–8.1 days ^[11].

Pulsatility preserved (n=healthy men, 20–40 yr). A second study showed that single subcutaneous doses of 60 or 90 micrograms/kg raised trough/basal GH approximately 7.5-fold and mean GH by roughly 46%, with IGF-1 up by approximately 45% one week later — and that the frequency and magnitude of pulsatile GH secretion were unaltered throughout ^[12].

Reported effects, cautions & safety

CJC-1295 has no compiled community-signal data in this desk's source material, so no anecdotal reports are presented. The cautions below come from the peer-reviewed record and regulatory documentation.

Safety cautions from the literature:

• No efficacy trial, no long-term safety data. CJC-1295's published human record consists of two pharmacology studies in small healthy-volunteer populations. There is no controlled trial of efficacy or safety for any outcome — disease, body composition, aging, or otherwise. Dosing protocols circulating in wellness and anti-aging contexts have no peer-reviewed human trial foundation ^[11][12].
• Development program was discontinued. The original ConjuChem DAC program that produced CJC-1295 was halted; a patient death during the development era is cited in connection with the discontinued Phase 2 program, though causal attribution to CJC-1295 was not established in the public record.
• Sustained IGF-1 elevation and cancer risk. Epidemiological evidence links higher IGF-1 levels to modestly increased risk of certain cancers. Sustaining IGF-1 above baseline for days to weeks from repeated dosing raises a theoretical oncologic concern that no short-term pharmacology study can address ^[8].
• Fluid retention, insulin sensitivity. GH excess is associated with sodium retention, edema, and effects on insulin sensitivity — the same GH/IGF-1 axis mechanisms that drive the theoretical value in body recomposition also produce these off-target effects.
• Regulatory review. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295. CJC-1295 is not recommended for the 503A compounding bulks list.
• Anti-doping prohibition. CJC-1295 is prohibited at all times in sport under WADA Section S2. Detection by LC-MS/MS and immuno-PCR assays is well established ^[9].
• DAC vs no-DAC confusion. Most community protocols conflate CJC-1295 DAC (multi-day half-life) with Modified GRF 1-29 (short-acting). Their pharmacokinetics are not interchangeable.

Where it fits in GH-axis research

CJC-1295 represents the GHRH-receptor (GHRH) route to GH release — the opposite track from ipamorelin's GHS-R1a mechanism. In the pharmacological logic of "stacking" the two, each peptide activates a different receptor to converge on the same pituitary cell; the combination data are limited to a mouse model mentioned in a 2026 orthopaedic narrative review ^[7]. Among the three compounds here, CJC-1295 has the most striking human pharmacology — days-long GH and IGF-1 elevation from a single dose — paired with the complete absence of any efficacy trial. Compare all three on the comparison page.